Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMAddition
jRCT2031220104Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) comparing 177Lu-PSMA-617 + standard of care with Standard of care alone (2 arms). Primary endpoint: Radiographic progression-free survival. Started Aug 2022; status: active, not recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031220104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220104.